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Antipsychotic treatment and neuregulin 1 -ErbB4 signalling in schizophrenia
Abstract
Evidence from genetic, transgenic and post-mortem studies has strongly supported the critical role that
neuregulin 1 (NRG1) and its ErbB4 receptor plays in the pathophysiology of schizophrenia. This article
aims to review current evidence regarding the effects of antipsychotic treatment on NRG1–ErbB4
signalling. NRG1 and ErbB4 knockout mice display abnormal behaviours relevant to certain features of
schizophrenia, which could be improved by antipsychotic (clozapine/haloperidol) treatment. In contrast to
most NRG1/ErbB4 knockout mice with a decreased NRG1–ErbB4 signalling, the majority post-mortem
studies showed an increased NRG1–ErbB4 signalling in schizophrenic patients. These differences could
be due to degrees of alteration in risk genes (subtle variations in patients vs pronounced alteration in
mutant mice) or the duration of the modification on NRG1 signalling. Various antipsychotics have
different effects on NRG1 and ErbB4 expression and signalling that are dependent on treatment duration.
Current evidence suggests that a chronic (12 weeks) antipsychotic treatment, at least in animal models,
could downregulate NRG1–ErbB4 signalling, although an upregulation is seen for a short-term treatment.
These effects may be due to multiple binding profiles with various G-coupled protein receptors (e.g.
dopamine, and serotonin receptors) of antipsychotics. Studies are needed to investigate the interactions
between NRG1–ErbB4 and the other signalling pathways (such as glutamatergic, GABAergic and
dopaminergic). Furthermore, the interactions between NRG1/ErbB4 and other schizophrenia
suspensibility genes under antipsychotic treatment also require investigation.
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Abstract
Evidence from genetic, transgenic and post-mortem studies have strongly supported
the critical role that neuregulin 1 (NRG1) and its ErbB4 receptor play in the
pathophysiology of schizophrenia. This article aims to review current evidence
regarding to the effects of antipsychotic treatment on NRG1-ErbB4 signalling. NRG1
and ErbB4 knockout mice display some schizophrenia-like behavioural abnormalities,
which could be improved by antipsychotic (clozapine/haloperidol) treatment. In
contrast to NRG1/ErbB4 knockout mice with a decreased NRG1-ErbB4 signalling,
the majority post-mortem studies showed an increased NRG1-ErbB4 signalling in
schizophrenia patients. These differences could be due to degrees of alteration in risk
genes (subtle variations in patients vs pronounced alteration in mutant mice) or the
duration of the modification on NRG1 signalling. Various antipsychotics have
different effects on NRG1 and ErbB4 expression and signalling dependent on
treatment duration. Current evidence suggests that a chronic (12 weeks) antipsychotic
treatment, at least in animal models, downregulates NRG1-ErbB4 signalling, although
an upregulation is seen for a short term treatment. Therefore, the dysfunctional
NRG1-ErbB4 signalling observed in schizophrenia is unlikely to be due to
antipsychotic therapy. Furthermore, multiple-receptor binding profiles (e.g. dopamine,
and 5-HT receptors) of antipsychotics may also contribute to their different influences
on NRG1-ErbB4 signalling. Studies are also needed to investigate the interactions
between NRG1-ErbB4 and the other signalling pathways (such as glutamatergic,
GABAergic and dopaminergic).

Key words: Schizophrenia; neuregulin-1; ErbB4 receptor, knockout mouse,
antipsychotics
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Abbreviations:
5-HT, Serotonin; BA, Brodmann areas; BACE1, a transmembrane endopeptidase βSite APP-cleaving enzyme 1; CNS, central nervous system; CYT, C-terminal
cytoplasmic tails; ErbB4, a membrane-associated tyrosine kinases, ErbB4 receptor
kinases; EGF, epidermal growth factor; Ig, immunoglobulin; NMDA, N-methyl-Daspartate; NRG1, neuregulin 1; PBLs, peripheral blood lymphocytes; PFC, prefrontal
cortex; PPI, prepulse inhibition; PSD95, post synaptic density protein 95; SNP,
single-nucleotide polymorphism.
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1. Introduction
Although the aetiology and pathophysiology of schizophrenia is still not fully
understood, it has been widely accepted that both genetic and environmental factors
play critical roles in the development of schizophrenia. Over the past decades, the
roles of genetic factors have been attracting increased attentions in schizophrenia
research. The neuregulin 1 (NRG1) gene has been identified as a candidate gene for
schizophrenia in several genetics studies (Li et al., 2006; Liu et al., 2005; Petryshen et
al., 2005; Stefansson et al., 2003; Williams et al., 2003; Yang et al., 2003). NRG1 is a
group of proteins that contains an epidermal growth factor (EGF)-like domain (α or β)
that signals by activating membrane-associated tyrosine kinases, especially the ErbB4
receptor kinases in the central nervous system (CNS) (Falls, 2003). An association
between ErbB4 gene and schizophrenia has also been reported (Silberberg et al.,
2006). NRG1-induced stimulation of the ErbB4 receptor plays critical roles in the
neuronal functions that are closely related to the development of schizophrenia,
mainly neuronal specification, neuronal migration, neuron-glial signalling, synapse
formation, synaptic transmission, and plasticity of the CNS (for review: see Harrison
and Law, 2006). Several studies found that animals with impaired NRG1-ErbB4
signalling displayed schizophrenia-like behavioural abnormalities (Barros et al., 2009;
Dejaegere et al., 2008; Rimer et al., 2005; Savonenko et al., 2008; Stefansson et al.,
2002).

In clinics, various antipsychotic drugs, including typical and atypical antipsychotics,
are widely used to control schizophrenia symptoms. Typical antipsychotics are
effective to ameliorate the positive symptoms of schizophrenia mainly through
potently and specifically blocking the dopamine receptors (Kapur and Mamo, 2003;
4
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Strange, 2008). Atypical antipsychotics have some effects on positive and negative
symptoms, as well as cognitive deficits (Burton, 2006). Atypical antipsychotics have
binding profiles not only with dopaminergic receptors, but also with many other
receptors, including the serotonin (5-HT), α adrenergic, histamine H1, and muscarinic
M1 receptors (Mathews and David, 2007). In view of the relationships between
NRG1-ErbB4 function and the pathophysiology of schizophrenia, and between
antipsychotic treatment and schizophrenia symptoms, the key questions are whether
antipsychotic drugs regulate the NRG1-ErbB4 signalling, and how this regulation
contributes to their efficacy in controlling schizophrenia symptoms? It is very
interesting that schizophrenia patients with different NRG1 genotypes have been
reported to respond differently to typical antipsychotics (Kampman et al., 2004).
However, to date, not much attention has been paid on the effects of antipsychotic
drugs on NRG1-ErbB4 signalling. This paper will focus on reviewing the current
evidence regarding to the effects of antipsychotics on the alteration of NRG1-ErbB4
functions.

2. Methods
A reference search was performed across the Medline (January 2000 - November
2010) and ScienceDirect (January 2000 - November 2010) databases. Key words
included antipsychotic, individual drug names (chlorpromazine, trifluoperazine,
perphenazine, triflupromazine, fluphenazine, thiothixene, zuclopenthixol, haloperidol,
pimozide, melperone, loxapine, amisulpride, clozapine, risperidone, olanzapine,
quetiapine, ziprasidone, aripiprazole, paliperidone, sulpiride, and zotepine), crossreferenced with neuregulin 1, NRG1, and ErbB4. In addition, the reference lists of all
papers identified were reviewed.
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3. Structures of NRG1 isoforms
The NRG1 gene generates six types of protein (I-VI) and at least 31 isoforms in
humans, presumably due to multiple promoters and alternative splicing; each protein
type possesses a specific amino-terminal region. All six types of NRG1 isoforms have
an EGF-like domain, which is located in the membrane-proximal area of the
extracellular part. The type III isoforms contain a cysteine-rich domain (CRD) that
has a transmembrane domain. In the NRG1 types I, II, IV and V isoforms, an
immunoglobulin (Ig)-like domain connects with the N-terminal sequence and the
EGF-like domain. However, the N-terminal sequence of NRG1 types III and VI is
connected directly to the EGF-like domain. Then the EGF-like domain is connected
with a C-terminal transmembrane domain with or without the linker regions. In the
intracellular part, there are C-terminal regions (cytoplasmic tail) (Falls, 2003;
Harrison and Law, 2006; Mei and Xiong, 2008). In the proteolytic processing of
NRG1, a transmembrane endopeptidase β-Site APP-cleaving enzyme 1 (BACE1) is
involved in cleaving the NRG1 molecule, releasing an extracellular domain of the
NRG1 molecule (except in the case of NRG1 type III) (Hu et al., 2006; Willem et al.,
2006). In addition, the remaining membrane-bound NRG1 fragment can be cleaved by
Aph1B/C-γ-secretase, generating an intracellular domain that can relocate into the
nucleus to regulate gene transcription (Bao et al., 2003).

4. Abnormal behaviours of animals with deficient NRG1-ErbB4 signalling could
be reversed by antipsychotic treatment
In the last decade, animal studies have shown that animals with abnormal NRG1ErbB4 functions display schizophrenia-like behavioural abnormalities, including
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hyperactivities in the novel open-field test and the alternating-Y maze (Barros et al.,
2009; Duffy et al., 2008; Gerlai et al., 2000; O'Tuathaigh et al., 2007; Rimer et al.,
2005; Stefansson et al., 2002; van den Buuse et al., 2009), deficits in prepulse
inhibition (PPI) level (Barros et al., 2009; Dejaegere et al., 2008; Hong et al., 2008;
Savonenko et al., 2008; Stefansson et al., 2002; van den Buuse et al., 2009), and
lateral inhibition (Rimer et al., 2005), as well as impaired social activities
(O'Tuathaigh et al., 2007). These reports provided evidence supporting the potential
roles of mutations in NRG1 and ErbB4 genes as risk factors for schizophrenia.
Importantly, some of the behavioural abnormalities caused by NRG1 and ErbB4
knock-out could be normalised by administration of antipsychotics (Table 1). For
example, it has been reported that treatment with clozapine can reverse the
hyperactivity of NRG1 TMc-mutant mice in the novel open-field test and in the cross
maze test (Stefansson et al., 2002). The effects of clozapine on suppressing
hyperactivity have also been observed in open-field and running wheel tests in the
NRG1 Ig-like domain mutant mice (Rimer et al., 2005), and in novelty-induced
hyperactivity in BACE1-knockout mice. Although the deficits in PPI have been
observed in NRG1 EGF- and BACE1-knockout mice, the effects of clozapine on
improving PPI have been observed in BACE1-knockout mice (Savonenko et al.,
2008), but not in NRG1 EGF-mutant mice (Stefansson et al., 2002). Furthermore,
deficits of PPI could be reversed to normal level both haloperidol or clozapine in
Aph1B/C-γ-secretase-disturbed mice (Dejaegere et al., 2008). Impaired lateral
inhibition in NRG1 Ig-like domain mutant mice could also be improved by clozapine
(Rimer et al., 2005). In addition, clozapine could reverse the abnormalities in ErbB4deficient mice, including decreased anxiety in the open field test, more aggressive
activities in the resident-intruder assay and lower PPI level (Barros et al., 2009).
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5. Dysregulated NRG1-ErbB4 signalling in schizophrenia: is it caused by
antipsychotic treatment?
A number of post-mortem studies examined the expression of NRG1 (including the
protein level and its mRNA) in the brain of schizophrenia patients. Although the
results are not completely consistent, they did provide evidence to show abnormal
NRG1-ErbB4 signalling contributing to the pathophysiology of schizophrenia (Table
2). Hashimoto et al. first reported an increase of the mRNA expression of NRG1 type
I isoform, and a decrease in the ratios of type II/I and type II/III mRNA expressions in
the prefrontal cortex (PFC) of schizophrenia patients (Hashimoto et al., 2004). These
decreased rations of type II/I and type II/III expressions may indicate a relatively
decreased expression of type II isoform in schizophrenia (Hashimoto et al., 2004). In
a following study, the levels of mRNA for NRG1 type I was confirmed to be elevated
(34%) in the hippocampus of schizophrenia patients (Law et al., 2006). Importantly,
Chong et al. have also found that the protein level of the NRG1 intracellular part
increased by about 20% only in the PFC of schizophrenia patients, but not in patients
with bipolar disorders and depression (Chong et al., 2008). In contrast, a recent study
demonstrated that the gene expression of NRG1 type I isoform decreased in the PFC,
Brodmann area 10 (BA10) (53.2%), and the expression of NRG1 type II isoform
increased in BA10 (193%) of elderly schizophrenia patients (Parlapani et al., 2010).
In addition, the NRG1α mRNA expression was found to be decreased in the white
matter and grey matter of the PFC in schizophrenia patients (Bertram et al., 2007).

ErbB4 receptor expression was also shown to be abnormal in schizophrenia patients.
A post-mortem study has shown that the protein expression of the full-length ErbB4
receptor was increased by nearly 30% in the PFC of schizophrenia patients (Chong et
8
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al., 2008). In addition, another study has reported that the expression of ErbB4
receptor isoforms that contain the C-terminal cytoplasmic tails (CYT)-1 domain
significantly increased in the dorsolateral PFC of schizophrenia patients (Silberberg et
al., 2006). Law and colleagues also pointed out that the mRNA of ErbB4 isoforms
containing CYT-1 domain and a metalloprotease cleavable extracellular domain were
promoted in the dorsolateral PFC of schizophrenia patients (Law et al., 2007).
Interestingly, Hahn et al. (2006) have demonstrated that, although the expression of
both NRG1 and ErbB4 receptors did not significantly change in the PFC in
schizophrenic subjects compared to normal subjects, the phosphorylation and the
activation of downstream signalling of the ErbB4 receptor was elevated. These results
suggested an elevated NRG1-ErbB4 signalling in the brain of schizophrenia patients.

NRG1 expression was also studied in the peripheral systems, and the results were not
consistent. It was reported that the expression levels of NRG1 transcript variants in
type I and type III isoforms significantly increased in peripheral blood lymphocytes
(PBLs) from schizophrenia patients (Petryshen et al., 2005). However, another study
reported a decrease of NRG1 mRNA expression in PBLs from schizophrenia patients
(Zhang et al., 2008).

In brief, although current reports are not completed consistent, the majority of studies
in schizophrenia patients suggest an enhanced NRG1-ErbB4 signalling in
schizophrenic patients through over expressions of NRG1 and ErbB4, or increased
phosphorylation of the ErbB4 receptor leading to the elevated interaction of ErbB4
and postsynaptic density protein 95 (PSD95). It has been suggested that enhanced
NRG1-ErbB4 signalling contributes to NMDA hypofunction in schizophrenia (Hahn
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et al., 2006). It should be noted that schizophrenia patients usually have undergone
chronic antipsychotic treatments, therefore one key question is whether elevated
NRG1-ErbB4 signalling observed in post-mortem studies is caused by antipsychotic
treatment. However, current results do not support this claim, since the majority of
post-mortem studies in schizophrenia have found no correlation between overexpressions of NRG1/ErbB4 and dosages of antipsychotic treatment (Chong et al.,
2008; Hahn et al., 2006; Hashimoto et al., 2004; Law et al., 2007; Law et al., 2006).
Furthermore, elevated expression of the NRG1 intracellular part was only observed in
the PFC of schizophrenia, but not bipolar disorders and depression, although bipolar
patients were also exposed to antipsychotics (Chong et al., 2008). Positive
associations between intronic SNPs (rs7598440, rs707284, rs839523) and elevated
mRNA expressions of ErbB4 isoforms containing a metalloprotease cleavable
extracellular domain (JM-a) and CYT-1 domain have been reported, which suggests a
splice-variant specific expression of ErbB4 in the brain in schizophrenia (Law et al.,
2007). Splice variant-specific alteration of NRG1 gene expression was also observed
in schizophrenia (Law et al., 2006). It is important that chronic treatment of
antipsychotics has been reported to decrease NRG1-ErbB4 signalling (Hahn et al.,
2006; Pan et al., 2010) (see below for details).

6. The effects of antipsychotic treatment on NRG1-ErbB4 signalling
Several studies (Table 3) have also demonstrated that NRG1-ErbB4 expression could
be altered by administration of antipsychotic drugs in normal subjects. In an in vivo
animal study, four-week treatment with haloperidol increased the expression of NRG1
and ErbB4, while clozapine reduced the expression of NRG1 isoforms in the normal
rat PFC (Wang et al., 2008). On the other hand, four-week treatment with both
haloperidol and clozapine increased NRG1 and ErbB4 expressions in the
10
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hippocampus (Wang et al., 2008). In the same study, four-week treatment with
risperidone increased the protein levels of both NRG1 isoforms and ErbB4 receptors
in the hippocampus, but not in the PFC (Wang et al., 2008). Additionally, in a clinical
study, after a 2-week treatment with risperidone and quetiapine, NRG1 mRNA
expression of PBLs of first-onset schizophrenia patients (who has not take
antipsychotics before) significantly increased compared to the levels before
antipsychotic drug therapies (Zhang et al., 2008). Moreover, an in vitro study has
shown that NRG1 protein expression increased in human fetal brain aggregates after
being exposed to clozapine for three weeks; however, the expression of NRG1
proteins did not change following exposure to haloperidol (Chana et al., 2009). In
addition to the finding that NRG1-induced ErbB4 activation was significantly
enhanced in the PFC of schizophrenia patients (Hahn et al., 2006), it is very
interesting that NRG1-induced ErbB4 activation was significantly reduced by a 12weeks treatment with haloperidol in mouse brains (Hahn et al., 2006). Recently we
examined the effects of short-term or chronic treatment with aripiprazole, haloperidol
and olanzapine on the expression of NRG1 and ErbB4 in rat brains (Pan et al., 2010).
We found that 1-week treatment with olanzapine significantly increased the protein
expression of NRG1 type I, and type III in the hippocampus (unpublished data);
however, 12-week treatment with aripiprazole and haloperidol significantly decreased
the protein expression of NRG1 types I, II III and the ErbB4 receptor in the PFC.
Haloperidol treatment for 12 weeks also significantly reduced NRG1 type III
expression in the hypothalamus (Pan et al., 2010). These results suggested that, while
relatively short-term (1-4 weeks) treatment with antipsychotics might increase the
expression of NRG1 and ErbB4, chronic antipsychotic treatment (12 weeks) would
attenuate NRG1-ErbB4 signalling.
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7.

Summary

In general, the proposition that dysregulation of NGR1-ErbB4 signalling is involved
in the pathophysiology of schizophrenia is supported by evidence from studies in both
knockout (Nrg1-/+/ErbB4-/+) mouse models and post-mortem brains of schizophrenia
patients. However, findings from the knowout mouse models are contradictory to
those findings obtained from post-mortem studies that, in contrast to NRG1/ErbB4
mutant mice with a decreased NRG1-ErbB4 signalling that present schizophrenia-like
abnormal behaviours, schizophrenia patients displayed an increased NRG1-ErbB4
signalling. These differences are partly due to the fact that patients’ risk genotypes
have only some subtle variations, while transgenic mice have a pronounced gene
alteration (Banerjee et al., 2010), or partly due to the duration of the modification of
NRG1 signalling (Savonenko et al., 2008). Furthermore, dysregulated NRG1-ErbB4
signalling in schizophrenia might interact with other signalling pathways such as
glutamatergic, GABAergic and dopaminergic pathways (Banerjee et al., 2010;
Buonanno, 2010). It is important that antipsychotic drugs are able to reverse some
abnormal behaviours in NRG1 and ErbB4 mutant mice, and affect the expression of
NRG1/ErbB4 and the functioning of NRG1-ErbB4 signalling. It is worth noting that
none of the antipsychotic drugs can directly act on ErbB4 receptors; the exact
mechanisms of antipsychotics on NRG1-ErbB4 signalling are not clear. Although all
antipsychotic drugs largely target dopamine receptors (Kapur and Mamo, 2003),
atypical antipsychotics also have binding profiles on other receptors (such as 5-HT
and cholinergic receptors), which might explain why various antipsychotics have
different effects on NRG1 and ErbB4 expressions. Further studies investigating the
exact mechanisms of these regulations, in particular interactions between

12

13
NRG1/ErbB4 with other neurotransmitter systems, will improve our understanding of
the aetiology of schizophrenia as well as the treatment of this devastating disease.
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Table 1. Effects of antipsychotics on behavioural abnormalities in animals with impaired
NRG1-ErbB4 signalling.
Studies

Treatment

Results

Clozapine

Clozapine reversed the increased activity of the NRG1 TMc-mutant
mice in the novel open-field test and T-maze test.

Rimer et al.,
2005

Clozapine

The activity of the NRG1 Ig-mutant mice was affected by clozapine
more than the controls in the open-field and running wheel test.

Dejaegere et
al., 2008

Haloperidol,
Clozapine

Savonenko et
al., 2008

Clozapine

Clozapine selectively normalised PPI deficits and attenuated
novelty-induced hyperactivity occurring in BACE1-knockout mice.

Barros et al.,
2009

Clozapine

Clozapine reversed the behavioural defects (such as decreased
anxiety in the open field test, aggressive activities in the residentintruder test and lower PPI level) in ErbB4-deficient mice.

Stefansson et
al., 2002

Haloperidol and clozapine normalised PPI deficit in Alph1 B/C γsecretase-disturbed mice to normal levels.
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Table 2. Alteration of the expression of NRG1 isoforms and the ErbB4 receptor in
schizophrenia
Studies

Results

NRG1 expression in the CNS

Hashimoto et al., 2004

(1) NRG1 type I expression increased in the PFC of
schizophrenia patients.
(2) Type II/I and type II/III ratios decreased in the PFC of
schizophrenia patients.

Law et al., 2006

NRG1 type I elevated in the PFC and the hippocampus in
schizophrenia patients.

Hahn et al., 2006

The expression of NRG1 and the ErbB4 receptor was not
different between schizophrenia patients and controls.

Bertram et al. 2007

The NRG1 isoform expression is significantly reduced in
white matter and gray matter of the PFC of schizophrenia
patients.

Chong et al., 2008

NRG1 expression increased in the PFC of schizophrenia
patients.

Parlapani et al., 2010

(1) Expression of NRG1 type I decreased in BA10 of
schizophrenia patients.
(2) Expression of type II increased in BA10.

NRG1 expression in the peripheral system
Petryshen et al., 2005

Expression of NRG1 type I and type III increased in PBLs of
schizophrenia patients

Zhang et al., 2008

NRG1 expression in PBLs of schizophrenia patients was
lower than control groups before any antipsychotic
treatment.

ErbB4 receptor expression
Hahn et al., 2006

ErbB4 expression in the brain of schizophrenia patients did
not change, but the phosphorylation of the ErbB4 receptor
elevated.

Silberberg et al., 2006

ErbB4 receptors isoforms that contain the CYT-1 domain
over-expressed in the dorsolateral PFC of schizophrenia
patients.

Law et al. 2007

The mRNA of ErbB4 isoforms containing CYT-1 and JM-a
domain increased in the dorsolateral PFC of schizophrenia
patients

Chong et al., 2008

ErbB4 protein expression increased in the PFC of
schizophrenia patients.
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Table 3. Alteration of the expression of NRG1 isoforms and the ErbB4 receptor after
antipsychotic treatment.
Studies

Treatment
duration

Treatments

Results

Zhang et al.,
2008

2 weeks

Quetiapine,
risperidone

NRG1 expression in PBLs of schizophrenia patients increased
after quetiapine and risperidone treatment.

Wang et al.,
2008

4 weeks

Haloperidol,
clozapine,
risperidone

Haloperidol increased the expression of NRG1 and ErbB4,
clozapine decreased NRG1 expression in the rat PFC;
haloperidol and clozapine increased NRG1and ErbB4 in the
rat hippocampus; risperidone increased NRG1-ErbB4
expression in the hippocampus.

Chana et al.,
2009

3 weeks

Clozapine,
haloperidol

NRG1 expression in normal human fetal brain aggregates
increased after exposure to clozapine, but not haloperidol.

12 weeks

Haloperidol

Haloperidol reduced the NRG1-induced ErbB4 activation in
mice brain.

Hahn et al.,
2006

Pan et al.,
2010

12 weeks

Aripiprazole,
olanzapine,
haloperidol

Aripiprazole and haloperidol decreased the protein expression
of NRG1 types I, II III and the ErbB4 receptor in the rat PFC;
haloperidol reduced NRG1 type III expression in the rat
hypothalamus.
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